News Breaks |
|
|
| October 23, 2012 |
| 08:10 EDT |  | BSX | Boston Scientific reports clinical endpoint data from PLATINUM Long Lesion trial
Boston Scientific Corporation reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent System in patients with long coronary lesions. Results were presented today by Paul S. Teirstein, M.D., of the Scripps Clinic in La Jolla, California, and Co-Principal Investigator of the trial, at the 24th Annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. The PLATINUM Long Lesion study met its primary endpoint of target lesion failure (TLF) at 12 months with a 3.2 percent rate for the PROMUS Element Stent in the per protocol population compared to a pre-specified performance goal of 19.4 percent (p<0.001) based on historical outcomes for the TAXUS Express Stent. The PROMUS Element Stent also demonstrated low event rates through two-year follow-up as evidenced by no myocardial infarction (MI or heart attack) and a 5.2 percent ischemia-driven target lesion revascularization (TLR) rate. There were no ARC definite/probable stent thrombosis events through two years. |
|
|
News For BSX From The Last 14 Days Check below for free stories on BSX the last two weeks. |
|
|
| May 21, 2013 |
| 11:49 EDT | | BSX | Boston Scientific data show Bronchial Thermoplasty benefits for up to five years
 Subscribe for More Information |
|
| 05:48 EDT | | BSX | OrbusNeich seizes Boston Scientific stents as part of patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 09:41 EDT | | BSX | Supreme Court agrees to hear Medtronic-Boston Scientific patent case
Reported by SCOTUSblog live blog of court orders and opinions. |
|
| May 16, 2013 |
| 16:13 EDT | | BSX | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 07:51 EDT |  | BSX | Boston Scientific price target raised to $12 from $9 at JMP Securities
JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. |
|
| 07:28 EDT |  | BSX | I/O Central to host a conference
Subscribe for More Information |
|
| May 14, 2013 |
| 15:33 EDT | | BSX | Boston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. |
|
| May 10, 2013 |
| 10:00 EDT |  | BSX | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:03 EDT | | BSX | Boston Scientific receives CEO Mark approval for Rhythmia mapping system
Subscribe for More Information |
|
| 05:46 EDT | | BSX | Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information |
| |
| May 9, 2013 |
| 12:04 EDT | | BSX | Boston Scientific says data show Watchman device superior to warfarin
Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN Left Atrial Appendage Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization. The data demonstrated significant reductions in both cardiovascular and all death compared to warfarin. The data were presented today as a late-breaking clinical trial at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions. |
|
| 09:27 EDT | | BSX | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
| May 8, 2013 |
| 07:38 EDT | | BSX | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
|
|
|
|
|
